Stabilus SE Proposes Dr. Frank Heinricht for Supervisory Board Leadership Role

The Supervisory Board of Stabilus SE has resolved to propose Dr. Frank Heinricht for election to the Supervisory Board at the Annual General Meeting scheduled for February 4, 2026. This strategic nomination comes as Dr. Stephan Kessel completes his planned three-term tenure and will not seek re-election, with his term expiring at the conclusion of the 2026 meeting.

Following a structured selection process conducted by the Remuneration and Nomination Committee under Dr. Ralf-Michael Fuchs, Dr. Heinricht emerged as the preferred candidate after careful consideration of the Supervisory Board's composition objectives, overall competence profile, and diversity concept. The board envisions that if elected by shareholders, Dr. Heinricht would not only succeed Dr. Kessel but also be elected as Chair of the Supervisory Board, subject to corresponding board resolution.

Dr. Heinricht brings over three decades of executive experience across multiple industrial sectors, including metals, specialty glass, and electrical industries. His most recent leadership role spanned from 2013 to 2024 as Chair of the Board of Management at Schott AG in Mainz, where he notably oversaw the successful initial public offering of Schott Pharma AG in 2023. Prior to this, he served on the Management Board of Heraeus Holding GmbH from 2003 to 2013, including six years as Chair of the Management Board at one of Germany's leading family-owned technology companies by revenue.

His earlier career includes serving as sole Managing Director of ATMEL Germany GmbH from 1998 to 2002, now part of Microchip Technology, and beginning his professional journey at Temic Telefunken microelectronic after earning his physics degree and doctorate from the Technical University of Berlin.

Dr. Heinricht's extensive governance experience includes approximately 15 years as Deputy Chair of the Advisory Board of the Wurth Group, along with current positions on the advisory board of Schwarz Unternehmenstreuhand KG and the supervisory board of B. Braun SE. This diverse background positions him to provide valuable oversight and strategic direction for Stabilus as it continues its growth trajectory in the motion control solutions market.

Dr. Stephan Kessel reflected on his tenure, noting Stabilus's significant growth through both organic expansion and strategic acquisitions, including the recent Destaco purchase, which has positioned the company as a leading industrial supplier of motion control solutions. He expressed confidence that Dr. Heinricht's leadership experience and industry expertise would benefit the company's continued development.

Dr. Ralf-Michael Fuchs emphasized the careful succession planning process, expressing confidence that Dr. Heinricht's extensive management experience and broad market knowledge would provide valuable impetus for Stabilus's further development. The company, headquartered in Koblenz, maintains a global production and distribution network with approximately 8,000 employees worldwide and generated revenues of EUR 1.3 billion in the 2024 fiscal year.

The invitation for the Annual General Meeting will be published in mid-December 2025, providing shareholders with detailed information about the proposed leadership transition and other agenda items. This planned succession represents a significant milestone for Stabilus as it positions itself for continued leadership in the competitive motion control solutions industry serving sectors including mobility, industrial machinery, automation, energy, construction, health, leisure, and furniture. More information about the company can be found at group.stabilus.com and ir.stabilus.com.